S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
The Next Big Crisis Is Here (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
The Next Big Crisis Is Here (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
The Next Big Crisis Is Here (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NASDAQ:VAXX

Vaxxinity - VAXX Stock Forecast, Price & News

$3.58
+0.53 (+17.38%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.94
▼
$3.62
50-Day Range
$1.31
▼
$3.58
52-Week Range
$1.24
▼
$8.35
Volume
542,347 shs
Average Volume
501,595 shs
Market Capitalization
$451.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Vaxxinity MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.02mentions of Vaxxinity in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$2.16 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.36 out of 5 stars

Medical Sector

1009th out of 1,055 stocks

Pharmaceutical Preparations Industry

492nd out of 519 stocks

See Top Rated MarketRank™ Stocks Here

VAXX stock logo

About Vaxxinity (NASDAQ:VAXX) Stock

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.

Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Stock News Headlines

January 28, 2023 | americanbankingnews.com
Vaxxinity, Inc. (NASDAQ:VAXX) Major Shareholder Sells $1,357,476.95 in Stock
January 19, 2023 | finance.yahoo.com
Why Shares of Vaxxinity Jumped This Week
January 28, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
January 5, 2023 | finance.yahoo.com
Vaxxinity to Present at the 2023 J.P. Morgan Healthcare Conference
December 31, 2022 | finance.yahoo.com
Estimating The Fair Value Of Vaxxinity, Inc. (NASDAQ:VAXX)
December 2, 2022 | finance.yahoo.com
Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612
November 10, 2022 | finance.yahoo.com
Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 3, 2022 | finance.yahoo.com
Vaxxinity to Host First Analyst and R&D Day in New York City on November 10, 2022
January 28, 2023 | Porter & Company (Ad)
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
November 1, 2022 | finance.yahoo.com
Vaxxinity to Present at Upcoming Investor Conferences in November
October 30, 2022 | finance.yahoo.com
Vaxxinity, Inc. (NASDAQ:VAXX) stock most popular amongst private companies who own 48%, while individual investors hold 21%
October 24, 2022 | finance.yahoo.com
Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia
October 11, 2022 | uk.finance.yahoo.com
Vaxxinity, Inc. (VAXX)
September 21, 2022 | finance.yahoo.com
Immunis Welcomes Dr. Peter Diamandis to the Executive Advisory Board - Yahoo Finance
September 19, 2022 | finance.yahoo.com
Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders
September 13, 2022 | globenewswire.com
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine - GlobeNewswire
September 13, 2022 | finance.yahoo.com
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
September 12, 2022 | globenewswire.com
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK) - GlobeNewswire
September 12, 2022 | finance.yahoo.com
Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
September 1, 2022 | globenewswire.com
Vaxxinity to Present at Upcoming Investor Conferences in September - GlobeNewswire
September 1, 2022 | finance.yahoo.com
Vaxxinity to Present at Upcoming Investor Conferences in September
August 29, 2022 | bizjournals.com
CureVac is back in the Covid-19 vaccine game, this time with 'lessons learned' - Boston Business Journal - The Business Journals
August 12, 2022 | finance.yahoo.com
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity - Yahoo Finance
August 12, 2022 | finance.yahoo.com
Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity
August 12, 2022 | finance.yahoo.com
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - Yahoo Finance
August 11, 2022 | seekingalpha.com
Vaxxinity GAAP EPS of -$0.14 beats by $0.24 (NASDAQ:VAXX) - Seeking Alpha
August 11, 2022 | globenewswire.com
Vaxxinity Reports Second Quarter 2022 Financial Results and Provides Corporate Updates - GlobeNewswire
See More Headlines
Receive VAXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter.

VAXX Company Calendar

Last Earnings
11/10/2022
Today
1/28/2023
Next Earnings (Estimated)
3/23/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VAXX
CUSIP
N/A
CIK
1851657
Web
www.vaxxinity.com
Phone
254-244-5739
Fax
N/A
Employees
89
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-137,180,000.00
Net Margins
N/A
Pretax Margin
-603,670.63%
Return on Equity
-100.72%
Return on Assets
-73.48%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
3.33
Quick Ratio
3.33

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
6,447.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.03 per share
Price / Book
3.48

Miscellaneous

Outstanding Shares
126,060,000
Free Float
44,889,000
Market Cap
$451.29 million
Optionable
Not Optionable
Beta
0.55

Key Executives

  • Mr. Louis Garfield Reese IV (Age 39)
    Co-Founder & Exec. Chairman
    Comp: $428.03k
  • Ms. Mei Mei Hu J.D. (Age 38)
    CEO & Director
    Comp: $428.03k
  • Dr. Ulo Palm M.D. (Age 65)
    Ph.D., Chief Medical Officer
    Comp: $551.19k
  • Mr. Jason Pesile CPA (Age 49)
    M.B.A., Sr. VP of Fin. & Accounting
  • Mr. Dwayne Soisson
    VP of Operations
  • Mr. Benjamin Matone
    VP of Investor Relations
  • Mr. Rene Paula Molina (Age 43)
    Gen. Counsel & Sec.
  • Mr. Jon Harrison
    Chief Gov. Officer
  • Mr. Mark Joinnides
    Chief of Staff
  • Ms. Amy B. Fix M.B.A.
    M.S., R.A.C., Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













VAXX Stock - Frequently Asked Questions

Should I buy or sell Vaxxinity stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxxinity in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VAXX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VAXX, but not buy additional shares or sell existing shares.
View VAXX analyst ratings or view top-rated stocks.

How have VAXX shares performed in 2023?

Vaxxinity's stock was trading at $1.40 on January 1st, 2023. Since then, VAXX stock has increased by 155.7% and is now trading at $3.58.
View the best growth stocks for 2023 here.

When is Vaxxinity's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our VAXX earnings forecast.

How were Vaxxinity's earnings last quarter?

Vaxxinity, Inc. (NASDAQ:VAXX) announced its quarterly earnings data on Thursday, November, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01.

When did Vaxxinity IPO?

(VAXX) raised $90 million in an initial public offering on Thursday, November 11th 2021. The company issued 6,000,000 shares at $14.00-$16.00 per share.

What is Vaxxinity's stock symbol?

Vaxxinity trades on the NASDAQ under the ticker symbol "VAXX."

How do I buy shares of Vaxxinity?

Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxxinity's stock price today?

One share of VAXX stock can currently be purchased for approximately $3.58.

How much money does Vaxxinity make?

Vaxxinity (NASDAQ:VAXX) has a market capitalization of $451.29 million and generates $70,000.00 in revenue each year. The company earns $-137,180,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis.

How can I contact Vaxxinity?

The official website for the company is www.vaxxinity.com. The company can be reached via phone at 254-244-5739 or via email at ir@vaxxinity.com.

This page (NASDAQ:VAXX) was last updated on 1/28/2023 by MarketBeat.com Staff